Why the study?
Does perindopril alter insulin sensitivity and lipoprotein metabolism in overweight, nondiabetic patients with essential hypertension?
Population
30 overweight (mean BMI 30.9 kg/m2), nondiabetic patients with essential hypertension
Comparison
Perindopril administered for 6 weeks vs Placebo administered for 6 weeks
Design
RCT, double-blind
Follow-up
6 weeks
Authors
Loading...
Perindopril may be used without insulin sensitivity concerns in overweight nondiabetic hypertensives; confirms metabolic neutrality of ACE inhibitors.
Does perindopril alter insulin sensitivity and lipoprotein metabolism in overweight, nondiabetic patients with essential hypertension?
Perindopril is metabolically neutral regarding insulin sensitivity, glucose, and lipids in overweight, nondiabetic patients with essential hypertension.
Böhlen et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: